The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective
Nephrology Dialysis Transplantation2007Vol. 22(5), pp. 1428–1436
Citations Over TimeTop 10% of 2007 papers
Abstract
Unless the cost of cinacalcet is considerably reduced, it is unlikely to be considered a cost-effective treatment for people with SHPT.
Related Papers
- → Calcium-Sensing Receptor Activation in Chronic Kidney Disease: Effects Beyond Parathyroid Hormone Control(2014)29 cited
- → Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction(2013)25 cited
- → Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?(2005)24 cited
- → Comparison of Hemodialysis Patient Outcomes Following Treatment with Paricalcitol Alone or in Combination with Cinacalcet(2008)2 cited
- → Cinacalcet in patients with secondary hyperparathyroidism; a review(2023)